These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 25271963)

  • 1. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor.
    Finlay MR; Anderton M; Ashton S; Ballard P; Bethel PA; Box MR; Bradbury RH; Brown SJ; Butterworth S; Campbell A; Chorley C; Colclough N; Cross DA; Currie GS; Grist M; Hassall L; Hill GB; James D; James M; Kemmitt P; Klinowska T; Lamont G; Lamont SG; Martin N; McFarland HL; Mellor MJ; Orme JP; Perkins D; Perkins P; Richmond G; Smith P; Ward RA; Waring MJ; Whittaker D; Wells S; Wrigley GL
    J Med Chem; 2014 Oct; 57(20):8249-67. PubMed ID: 25271963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
    Cross DA; Ashton SE; Ghiorghiu S; Eberlein C; Nebhan CA; Spitzler PJ; Orme JP; Finlay MR; Ward RA; Mellor MJ; Hughes G; Rahi A; Jacobs VN; Red Brewer M; Ichihara E; Sun J; Jin H; Ballard P; Al-Kadhimi K; Rowlinson R; Klinowska T; Richmond GH; Cantarini M; Kim DW; Ranson MR; Pao W
    Cancer Discov; 2014 Sep; 4(9):1046-61. PubMed ID: 24893891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.
    Ballard P; Yates JW; Yang Z; Kim DW; Yang JC; Cantarini M; Pickup K; Jordan A; Hickey M; Grist M; Box M; Johnström P; Varnäs K; Malmquist J; Thress KS; Jänne PA; Cross D
    Clin Cancer Res; 2016 Oct; 22(20):5130-5140. PubMed ID: 27435396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients.
    Remon J; Planchard D
    Future Oncol; 2015 Nov; 11(22):3069-81. PubMed ID: 26450446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.
    Jänne PA; Yang JC; Kim DW; Planchard D; Ohe Y; Ramalingam SS; Ahn MJ; Kim SW; Su WC; Horn L; Haggstrom D; Felip E; Kim JH; Frewer P; Cantarini M; Brown KH; Dickinson PA; Ghiorghiu S; Ranson M
    N Engl J Med; 2015 Apr; 372(18):1689-99. PubMed ID: 25923549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291.
    Thress KS; Brant R; Carr TH; Dearden S; Jenkins S; Brown H; Hammett T; Cantarini M; Barrett JC
    Lung Cancer; 2015 Dec; 90(3):509-15. PubMed ID: 26494259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells.
    Ku BM; Bae YH; Koh J; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Invest New Drugs; 2016 Aug; 34(4):407-15. PubMed ID: 27044261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients.
    Planchard D; Loriot Y; André F; Gobert A; Auger N; Lacroix L; Soria JC
    Ann Oncol; 2015 Oct; 26(10):2073-8. PubMed ID: 26269204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.
    Walter AO; Sjin RT; Haringsma HJ; Ohashi K; Sun J; Lee K; Dubrovskiy A; Labenski M; Zhu Z; Wang Z; Sheets M; St Martin T; Karp R; van Kalken D; Chaturvedi P; Niu D; Nacht M; Petter RC; Westlin W; Lin K; Jaw-Tsai S; Raponi M; Van Dyke T; Etter J; Weaver Z; Pao W; Singh J; Simmons AD; Harding TC; Allen A
    Cancer Discov; 2013 Dec; 3(12):1404-15. PubMed ID: 24065731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
    Shi P; Oh YT; Zhang G; Yao W; Yue P; Li Y; Kanteti R; Riehm J; Salgia R; Owonikoko TK; Ramalingam SS; Chen M; Sun SY
    Cancer Lett; 2016 Oct; 380(2):494-504. PubMed ID: 27450722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming acquired resistance of gefitinib in lung cancer cells without T790M by AZD9291 or Twist1 knockdown in vitro and in vivo.
    Liu Z; Gao W
    Arch Toxicol; 2019 Jun; 93(6):1555-1571. PubMed ID: 30993382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of highly potent and selective EGFR
    Yang T; Zhang W; Cao S; Sun S; Cai X; Xu L; Li P; Zheng Z; Li S
    Eur J Med Chem; 2022 Jan; 228():113984. PubMed ID: 34794818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and optimization of covalent EGFR T790M/L858R mutant inhibitors.
    Hoogenboom N; Demont D; de Zwart E; Verkaik S; Emmelot M; van de Kar B; Kaptein A; Barf T
    Bioorg Med Chem Lett; 2021 Nov; 52():128406. PubMed ID: 34624491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
    Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K
    Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of immunotherapy targeting the neoantigen derived from epidermal growth factor receptor T790M/C797S mutation in non-small cell lung cancer.
    Akazawa Y; Saito Y; Yoshikawa T; Saito K; Nosaka K; Shimomura M; Mizuno S; Nakamoto Y; Nakatsura T
    Cancer Sci; 2020 Aug; 111(8):2736-2746. PubMed ID: 32391625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
    Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY
    Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR Inhibitor.
    Kim TM; Song A; Kim DW; Kim S; Ahn YO; Keam B; Jeon YK; Lee SH; Chung DH; Heo DS
    J Thorac Oncol; 2015 Dec; 10(12):1736-44. PubMed ID: 26473643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer.
    Yun J; Hong MH; Kim SY; Park CW; Kim S; Yun MR; Kang HN; Pyo KH; Lee SS; Koh JS; Song HJ; Kim DK; Lee YS; Oh SW; Choi S; Kim HR; Cho BC
    Clin Cancer Res; 2019 Apr; 25(8):2575-2587. PubMed ID: 30670498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR T790M mutation testing within the osimertinib AURA Phase I study.
    Dearden S; Brown H; Jenkins S; Thress KS; Cantarini M; Cole R; Ranson M; Jänne PA
    Lung Cancer; 2017 Jul; 109():9-13. PubMed ID: 28577957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Let-7c regulated epithelial-mesenchymal transition leads to osimertinib resistance in NSCLC cells with EGFR T790M mutations.
    Li XF; Shen WZ; Jin X; Ren P; Zhang J
    Sci Rep; 2020 Jul; 10(1):11236. PubMed ID: 32641854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.